Page 14 - 南京医科大学自然版

第46卷第8期
·1120 · 南 京 医 科 大 学 学 报 2026年8月

是实现中晚期 HCC 降期治疗的有效手段。对于早 ［5］ ZHUANG H K，TANG C W，WANG W T，et al. Sitrava⁃
期反应良好的患者，应 MDT 动态评估肝功能、癌栓 tinib targets TYRO3 to augment the antitumor immune re⁃
退缩及剩余肝体积，抓住转化窗口期积极实施根治 sponse of PD⁃1 blockade in hepatocellular carcinoma［J］.
性手术，以期获得最佳的长期生存获益。 Clin Cancer Res，2025，31（22）：4763-4778
利益冲突声明： ［6］ ZHANG W，LIU Z R，LIU H J，et al. The impact of im⁃
所有作者均声明在本文的研究、撰写及投稿过程中，不 mune checkpoint inhibitors on prognosis in unresectable
存在任何与本文研究内容相关的商业、经济及其他形式的利 hepatocellular carcinoma treated with TACE and lenva⁃
tinib：a meta ⁃ analysis［J］. Front Immunol，2025，16：
益冲突。
1573505
Conflicts of Interests：
［7］ XUE M，WU Y Q，TANG Y Y，et al. Efficacy and safety of
All authors declare that there are no conflict of interests，in⁃
TACE combined with lenvatinib and PD⁃1 inhibitor in in⁃
cluding any commercial，financial，or other forms of interests，re⁃
termediate⁃stage HCC exceeding the up⁃7 criteria：a retro⁃
lated to the research，writing，or submission of this article.
spective cohort study［J］. Front Immunol，2025，16：
作者贡献声明：
兰欣负责研究方案的设计、临床数据的采集与整理、统 1560750
计学分析以及论文初稿的撰写；韩国勇负责临床诊断指导、 ［8］ GOH M J，PARK H C，YU J I，et al. Impact of intrahepatic
手术方案评估、病例复核以及论文主要学术内容的修改；吴 external beam radiotherapy in advanced hepatocellular
金道负责研究课题的整体构思、论文质量把关、经费支持及 carcinoma patients treated with tyrosine kinase inhibi⁃
最终版本的审定校稿。 tors［J］. Liver Cancer，2023，12（5）：467-478
Author’s Contributions： ［9］ SHU P，WANG F，WANG X. Case report：abscopal effect
in a patient with refractory metastatic hepatocellular carci⁃
LAN Xin designed the study protocol，collected and orga⁃
noma treated with stereotactic body radiotherapy and PD⁃1
nized the clinical data，performed statistical analysis，and drafted
inhibitor［J］. Front Immunol，2025，16：1536689
the initial version of the manuscript. HAN Guoyong provided
clinical diagnostic guidance ，evaluated surgical strategies ， ［10］HWANG S Y，LEE S L，LIU H Q，et al. Second⁃line treat⁃
ment after failure of immune checkpoint inhibitors in he⁃
reviewed the cases，and revised the core academic content of the
paper. WU Jindao conceived the overall research framework ， patocellular carcinoma：tyrosine kinase inhibitor，retrial
of immunotherapy，or locoregional therapy?［J］. Liver Can⁃
ensured the quality of the manuscript ，provided financial
cer，2024，13（3）：246-255
support，and critically reviewed and finalized the manuscript.
［11］WANG M L，SUN M Q，DONG H，et al. Elemene aug⁃
［参考文献］
ments the effects of anti⁃PD⁃1 immunotherapy on hepato⁃
［1］ ZHANG W W，TONG S，HU B Y，et al. Lenvatinib plus cellular carcinoma by regulating the miR⁃ 130a⁃5p/SPP/
anti⁃PD⁃ 1 antibodies as conversion therapy for patients MHC ⁃ I axis［J］. Adv Sci（Weinh），2026，13（11）：
with unresectable intermediate ⁃ advanced hepatocellular e11887
carcinoma：a single⁃arm，phase Ⅱ trial［J］. J Immunother ［12］YANG X G，DENG L W，ZHAO Y，et al. TACE and tyro⁃
Cancer，2023，11（9）：e007366 sine kinase inhibitors with or without PD⁃1 inhibitors as
［2］ ZHANG X Y，CAI H Z，PENG W，et al. Lenvatinib plus first⁃line therapy for intermediate⁃advanced HCC：a multi⁃
transarterial chemoembolization and PD ⁃ 1 inhibitors as center real⁃world cohort study［J］. Hepatol Int，2026，20
conversion therapies for unresectable intermediate ⁃ ad⁃ （2）：384-395
vanced hepatocellular carcinoma：a phase 2 trial and ex⁃ ［13］WANG H，QIAN Y W，DONG H，et al. Pathologic assess⁃
ploratory biomolecular study［J］. Sig Transduct Target ment of hepatocellular carcinoma in the era of immuno⁃
Ther，2026，11（1）：37 therapy：a narrative review［J］. Hepatobiliary Surg Nutr，
［3］ CHEN R Y，LI Q，XU S S，et al. Modulation of the tumour 2024，13（3）：472-493
microenvironment in hepatocellular carcinoma by tyro⁃ ［14］DUAN X H，LI H，KUANG D L，et al. Transcatheter arte⁃
sine kinase inhibitors：from modulation to combination rial chemoembolization plus apatinib with or without cam⁃
therapy targeting the microenvironment［J］. Cancer Cell relizumab for unresectable hepatocellular carcinoma：a
Int，2022，22（1）：73 multicenter retrospective cohort study［J］. Hepatol Int，
［4］ YANG X B，XU H F，ZUO B Y，et al. Downstaging and re⁃ 2023，17（4）：915-926
section of hepatocellular carcinoma in patients with extra⁃ ［15］LIN K Y，ZHANG J X，LIN Z W，et al. Serum alpha⁃feto⁃
hepatic metastases after stereotactic therapy［J］. Hepato⁃ protein response as a preoperative prognostic indicator in
biliary Surg Nutr，2021，10（4）：434-442 unresectable hepatocellular carcinoma with salvage hepa⁃